Disclaimer: This is a recording from Bitesize Bio, which was originally recorded in the United Kingdom; the references to “Merck” within refer to (1) Merck KGaA, Darmstadt, Germany; (2) an affiliate of Merck KGaA, Darmstadt, Germany; or (3) one of the businesses of Merck KGaA, Darmstadt, Germany, which operate in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics.
For further information about our names in the U.S. and Canada and internationally, please refer to our disclaimer at emdgroup.com
About this Webinar
Multi-target screening can offer great insight into the genetic pathways involved in drug resistance and disease. RNAi and the fast pace of CRISPR technology development have brought sophisticated options for library screens, including the possibility of genome-wide pooled and arrayed screens for knockdown, knockout, knock-in and gene modulation. shRNA and CRISPRi allow for targeted suppression of gene function, while ORFs and CRISPRa offer a gain-of-function approach to screening. Both complement existing loss-of-function technologies such as efficient knockout using traditional CRISPR-Cas9. It is now also possible to take your screening to single-cell resolution using 10x Genomics compatible CRISPR guide vectors.
In this webinar, you will discover:
- An overview of the broad range of available functional genomic screening technologies, including traditional shRNA, ORF, and CRISPR KO;
- How to design successful and meaningful genomics screening experiments using the latest in CRISPR modulation tools;
- More about the power of innovative pooled CRISPR screening at single-cell resolution;
- The application of functional genomics screening to unravel complex pathways and disease states, and identify novel drug targets.
Speaker
Gurpreet Balrey, Ph.D.
Merck KGaA, Darmstadt, Germany
Head of Global Commercial Enablement and EMEA Business Head
Genomics
- Advanced gene editing
Duration:43min
語言:English
會話 1:提出 October 13, 2021
若要繼續閱讀，請登入或建立帳戶。
還沒有帳戶？